By Jaiveer Shekhawat (Reuters) -Shares of Neumora Therapeutics, which is backed by Amgen (NASDAQ:AMGN) and Japan's SoftBank (TYO:9984), fell in their market debut on Friday,...
By Ludwig Burger and Paul Arnold FRANKFURT (Reuters) - Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business...
(Reuters) - Drug developer Generate:Biomedicines, which uses artificial intelligence (AI) to find new treatments, said on Thursday it has raised $273 million from investors...
HSBC initiated coverage of 11 U.S. biopharmaceutical and healthcare stocks in a note to clients on Wednesday. Analysts assigned Actinium Pharmaceuticals Inc (NYSE:ATNM), Amgen...
By Deena Beasley (Reuters) - The U.S. Federal Trade Commission's decision on Friday to allow Amgen (NASDAQ:AMGN)'s takeover of Horizon Therapeutics (NASDAQ:HZNP) was the latest...
By Manas Mishra and David Shepardson (Reuters) - The U.S. Federal Trade Commission (FTC) has allowed Amgen (NASDAQ:AMGN) to continue its $27.8 billion acquisition of Horizon...
By Patrick Wingrove and Michael Erman (Reuters) -The Biden administration on Tuesday released its list of 10 prescription medicines that will be subject to the first-ever price...
Amgen (AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS® (sotorasib) with carboplatin and pemetrexed...